ClinicalTrials.Veeva

Menu

The Use of Amber Glasses in Improving Sleep

S

Surrey and Borders Partnership NHS Foundation Trust

Status

Completed

Conditions

Insomnia
Sleep Disturbance

Treatments

Device: Amber Glasses

Study type

Interventional

Funder types

Other

Identifiers

NCT04751019
IRAS 262339

Details and patient eligibility

About

The use of amber glasses will aid the patient to fall asleep without the need for the use of hypnotic medication.

Full description

Sleep disturbance and insomnia is extremely common and affects up to 30% of adults at any given time. Moreover, sleep disturbance is known to be particularly prevalent in patients suffering from mental illness including affective disorders, schizophrenia, anxiety (Baglioni, 2016). We hypothesise that the use of amber glasses will aid the time taken to fall asleep without the need for the use of hypnotic medication.A prospective study looking at 15 new patients admitted to one mental health ward will be undertaken. Data will be collected on twice weekly basis on the patient's use of: amber glasses alone, hypnotic medication alone or both. Hypnotic medication will include sedating antihistamines, benzodiazepines and non-benzodiazepine hypnotics such as zopiclone. Medication prescribed for dual purpose will be assumed to be used for the treatment of insomnia if given after 2300 hours. Each patient will be enrolled for a period of 4 weeks and the review of use and suitability will take place in ward review meetings.

Sleep quality will be assessed using the Pittsburgh Sleep Quality Assessment tool at baseline and at the 2 and 4 weeks. At the end of the study period, percentage use of amber glasses and zopiclone will be used to compare against a historical average of hypnotic use for the most recent 15 admissions over a similar 4 week period.

Enrollment

15 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age over 18 years
  • Male or female gender
  • Presentation of mental illness (of psychotic nature, severe depression or anxiety)
  • Able to provide informed consent

Exclusion criteria

  • Patient does not consent
  • High risk assessment of self-harm or harm to others

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems